Source link : https://newshealth.biz/health-news/talquetamab-regimens-boost-survival-in-multiple-myeloma/
Talquetamab (Talvey) plus daratumumab (Darzalex) with or without pomalidomide (Pomalyst) significantly improved survival outcomes over an active regimen for relapsed or refractory multiple myeloma, a phase III trial showed. Among patients who had previously received at least one line of therapy, estimated 24-month progression-free survival (PFS) rates reached 81.3% with talquetamab plus daratumumab and pomalidomide […]
The post Talquetamab Regimens Boost Survival in Multiple Myeloma first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-13 10:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8